No Data
No Data
Meheco's Unit Gets Nod to Market Sacubitril-Valsartan Sodium Tablets
The amount involved exceeds 0.5 billion yuan and the equity transfer dispute of China Meheco Group is still ongoing | Quick read of the announcement.
① China Meheco Group has appealed to the court regarding the acquisition of the remaining 30% equity in Jinlun Pharmaceutical (now named Hebei Tongyong) held by Wang Yibing; ② The amount involved in this lawsuit reaches 0.51 billion yuan.
[Brokerage Focus] CMB International indicates that China Meheco Group has started a valuation recovery.
Jinwu Financial News | China Merchants International states that the MSCI Chinese Medical Index has risen 5.3% year-to-date as of early 2025, outperforming the MSCI Chinese Index by 0.9%. Benefiting from overseas interest rate cuts and improvements in the domestic macro environment, the pharmaceutical sector, as a highly elastic industry, is expected to outperform the market in 2025. The Category C medical insurance directory is set to be implemented within the year, and Innovative Drugs will benefit from better payment conditions through commercial health insurance coverage. The bidding for Medical Devices is accelerating its recovery, which will drive the profit recovery of domestic medical device companies. The bank is Bullish about the recovery of industry valuations. It recommends buying WUXI APPTEC (02359, 603259 CH).
Zhaoyin International: Bullish on the valuation repair of the China Meheco Group Industry, recommending to Buy WUXI APPTEC (02359) and others.
Cinda International believes that China will become a necessary place for overseas pharmaceutical companies to seek innovative drug pipelines, and innovative drugs from China will play an increasingly important role on the international stage.
China Meheco Group (SHSE:600056) Shareholders Notch a 14% CAGR Over 3 Years, yet Earnings Have Been Shrinking
Announcement on the pre-reduction of 2024 results